SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...
SAN ANTONIO – The use of circulating tumor cell (CTC) count to guide the choice between chemotherapy and endocrine...
Most were able to conceive and more than 60 percent gave birth SAN ANTONIO – Breast cancer patients who...
SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in...
SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine...
SAN ANTONIO – Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the...
SAN ANTONIO – Non-Hispanic Black women with hormone receptor (HR)-positive/HER2-negative, lymph node-positive breast cancer had worse outcomes compared to...
SAN ANTONIO – Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy...
Assay can also help identify patients who may benefit from ovarian suppression therapy SAN ANTONIO – Among premenopausal women...